Wang 2013.

Methods	Single‐centre RCT 2 arms Quality score: B
Participants	n = 82 participants with metastatic or locally recurrent gastric cancer ECOG 2: 8.5%
Interventions	S‐1 +paclitaxel: S‐1 depending on body surface area (BSA < 1.25 m2: 80 mg/d; BSA 1.25 to < 1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice daily) d 1‐14, paclitaxel 60mg/m2 d 1,8,15, repeated at d 29 versus S‐1: S‐1 depending on body surface area (BSA < 1.25 m2: 80 mg/d; BSA 1.25 to <1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice daily) d 1‐14, repeated at d 29
Outcomes	Overall survival Progression‐free survival Response rate Toxicity
Notes	Second‐line therapy with cisplatin or irinotecan in more than half of the patients
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated, random sequence
Allocation concealment (selection bias)	Low risk	Consecutively numbered opaque sealed envelopes
Incomplete outcome data (attrition bias) efficacy	Low risk	No patients lost to follow‐up and all outcomes could be confirmed
Incomplete outcome data (attrition bias) safety	Low risk	No patients lost to follow up and all outcomes could be confirmed
Selective reporting (reporting bias)	Low risk	OS, PFS, ORR, safety
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	High risk	Tumor assessment was undertaken with CT or MRI consistently every 2 months by principal investigators